Lianna Orlando, PhD

Title: Senior Director of Research

Organization: CureDuchenne

Bio: Lianna Orlando, PhD, is CureDuchenne’s Senior Director of Research, where she helps identify and evaluate strategic investments aimed at developing treatments for Duchenne Muscular Dystrophy. Prior to CureDuchenne, Lianna was at the Muscular Dystrophy Association (MDA), where she oversaw basic, translational, and clinical grant programs, including MDA’s venture philanthropy program, and Fidelity Biosciences Research Initiative (FBRI), focusing on funding research programs in neurodegenerative diseases. Before leaving academia, Lianna was a junior faculty member in the Neurology Department at Massachusetts General Hospital. She completed her doctorate in Neurobiology from Harvard University, and a select master’s degree in Medicine from Harvard Medical School. She has taught both undergraduates and medical students at Harvard, and worked as a freelance science writer for disease foundations and scientific journals. She holds B.S. degrees in Chemistry and in Magazine Journalism from Syracuse University (Summa Cum Laude/Phi Beta Kappa).

2021 FUTURES: Exon Skipping Panel

Information and updates on exon skipping therapies and research from experts in the Duchenne community.

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Kevin Eggan, PhD

Group Vice President, Head of Research and Early Development

BioMarin

See more from same speaker

Leslie Magnus, MD

Vice President, Medical Affairs

NS Pharma

See more from same speaker

James McArthur, PhD

President and Chief Executive Officer

PepGen

See more from same speaker

Lianna Orlando, PhD

Senior Director of Research

CureDuchenne

See more from same speaker

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

2024 FUTURES – Therapies to Preserve and Protect Muscle

Presentations covering therapies aiming to preserve and protect muscle in Duchenne, including anti-inflammatory agents, muscle stabilizers, and other mechanisms with relevant updates from companies in the space.

 

Karyn Koladicz, MD

Executive Medical Director for Medical Affairs, Neurology PTC Therapeutics

See more from same speaker

Lianna Orlando, PhD

Senior Director of Research

CureDuchenne

See more from same speaker

Abby Bronson

Vice President, Patient Advocacy & External Innovation

Edgewise Therapeutics

See more from same speaker

Stanley Iyadurai, MD, PhD

Sr VP Medical Affairs and Drug Discovery

Catalyst

See more from same speaker

Scott Baver, PhD

Head of Medical Affairs

ITF Therapeutics

See more from same speaker

Mark Awadalla

Vice President of Clinical Operations

Capricor

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

2024 FUTURES Exon skipping

A brief introduction on the rationale behind exon skipping therapies, followed by an overview of current and investigative exon skipping therapies.
Key insights were shared by Dr. Angel Angelov, Dr. Ash Dugar, Lianna Orlando, PhD, Dr. Kevin M. Flanigan, Laura Torrente, PhD, Alayna Tress, MPH, Karin Lucas, PhD, Mahasweta Girgenrath, Phd, Jessica Duis, MD, Husam Younis, PharmD, PhD.

Lianna Orlando, PhD

Senior Director of Research

CureDuchenne

See more from same speaker

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Kevin Flanigan, MD

Director, Center for Gene Therapy Nationwide Children's Hospital

See more from same speaker

Karin Lucas, Ph.D

West Medical Science Liaison Team Lead, Global Medical Affairs Sarepta Therapeutics

See more from same speaker

Laura Torrente, PhD

See more from same speaker

Alayna Tress, MPH

See more from same speaker

Mahasweta Girgenrath, Phd

See more from same speaker

Jessica Duis, MD

See more from same speaker

Husam Younis, PhD

See more from same speaker

Dr. Angel Angelov

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

2024 FUTURES New Therapeutic Approaches to Address Unmet Needs

Presentations on early-stage research and development companies working on approaches to address the unmet therapeutic needs in the Duchenne community.

Sharif Tabebordbar, PhD

See more from same speaker

Lianna Orlando, PhD

See more from same speaker

Ye Liu, PhD

See more from same speaker

Courtney Young, PhD

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years